Aprea Therapeutics (NASDAQ:APRE) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings results on Tuesday. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.20, Zacks reports. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million.

Aprea Therapeutics Trading Up 2.3 %

NASDAQ APRE opened at $2.24 on Thursday. The business’s 50 day moving average is $3.10 and its two-hundred day moving average is $3.25. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $6.80. The stock has a market capitalization of $12.17 million, a price-to-earnings ratio of -0.80 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.